The purpose of this study was to compare the Quantiferon-TB Gold Plus test analysed with chemiluminescence immunoassay (CLIA) to immunoassay (EIA). One hundred and twenty-five clinical specimens submitted to Karolinska University Hospital for Quantiferon-TB Gold Plus analysis were used to analyse agreement of the CLIA and EIA assays. The imprecision on CLIA was determined by analysis of pooled clinical samples of antigen tubes (TB1 and TB2), a reference material from National Institute for Biological Standards and Control (NIBSC 82/587) and two controls of the test. Recovery on CLIA was determined by analysis of the TB1 and TB2 samples and NIBSC 82/587. Concordant results were obtained for 110 (88.0%) of 125 samples with cut-off including a borderline range. With no borderline range, 121 of 125 samples (96.8%) showed concordant results. Repeatability had a coefficient of variation (CV) of 14.9%. Reproducibility for pooled clinical samples TB1 and TB2 had a CV of 10.5% and 11.0%, respectively, and for the NIBSC 82/587 7.45%, and kit controls 31.0% respective 12.2%. Overall recovery had a mean of 94.1% (SD 12%). We concluded that Quantiferon-TB Gold Plus analysed with the CLIA assay shows good concordance with EIA and acceptable imprecision.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apm.13025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of QuantiFERON-TB Gold for the Diagnosis of Infection in HTLV-1-Infected Patients.
Viruses
November 2024
Laboratório Avançado de Saúde Pública, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz (Fiocruz-BA), Salvador 40296-710, Bahia, Brazil.
Human T-cell leukemia virus type 1 (HTLV-1) is associated with an increased risk of tuberculosis (TB). This study aimed to evaluate the performance of the QuantiFERON-TB Gold (QFT) test for the diagnosis of (MTB) infection in HTLV-1-infected individuals. HTLV-1-infected participants were divided into four groups: HTLV-1-infected individuals with a history of tuberculosis (HTLV/TB), individuals with positive HTLV and tuberculin skin tests (HTLV/TST+) or negative TST (HTLV/TST-), and HTLV-1-negative individuals with positive TST results (HN/TST+).
View Article and Find Full Text PDFPredictive Markers of Incident Tuberculosis in Close Contacts in Brazil and India.
J Infect Dis
January 2025
Programa de Pós-graduação em Ciências da Saúde, Universidade Federal da Bahia, Salvador, Brazil.
There are insufficient predictors of progression to tuberculosis among contacts. A case-control study within RePORT-Brazil matched 20 QuantiFERON-positive progressors and 40 non-progressors by sex, age, and exposure duration. Twenty-nine cytokines were measured by Luminex in QuantiFERON-TB Gold Plus supernatants collected at baseline and evaluated using machine learning for tuberculosis prediction.
View Article and Find Full Text PDFDiscordance of 3rd and 4th generation QuantiFERON-TB Gold assays by pregnancy stages in India.
J Clin Tuberc Other Mycobact Dis
February 2025
Weill Cornell Medicine, Center for Global Health, 402 East 67th Street, 2nd Floor, New York, NY 10065, USA.
Background: Pregnancy and HIV affect CD4+ T lymphocytes and impact performance of QuantiFERON-TB Gold (QFT). We compared the results of QFT with QuantiFERON-TB Gold Plus (QFT-Plus), which also measures CD8+ responses to TB antigens, during pregnancy and postpartum.
Methods: We screened 516 pregnant women for TB infection (TBI) with IGRA.
Comparison of two interferon-gamma release assays for pediatric tuberculosis infection.
J Pediatric Infect Dis Soc
January 2025
Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, USA.
Introduction: Identifying tuberculosis infection (TBI) using interferon-gamma release assays (IGRAs) is a primary component of clinical and public health efforts to prevent pediatric tuberculosis. Pediatric data comparing the two IGRAs in the United States are very limited. We compared the performance of the two IGRAs among a large pediatric cohort tested for TBI and assessed whether discordance might be due to quantitative results close to test cut-off values.
View Article and Find Full Text PDFLow concordance between QIAreach QuantiFERON-TB, a novel interferon-gamma release assay, and QuantiFERON-TB Gold Plus, in a population-based survey in Blantyre, Malawi.
J Clin Microbiol
December 2024
Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Unlabelled: Urgent improvements in the diagnosis and management of infection are required to reach End TB goals. Conventional interferon-gamma release assays (IGRAs), such as QuantiFERON-TB Gold Plus (QFT-Plus), require substantial laboratory infrastructure and large blood volumes, limiting use in high-burden settings. The QIAreach QuantiFERON-TB (QIAreach QFT) was developed to overcome these challenges but has not previously been evaluated in field conditions in a low-income, high-burden country, or at scale in children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!